The estimated Net Worth of Troy A. Ignelzi is at least 14.9 百万$ dollars as of 22 August 2023. Mr. Ignelzi owns over 1,500 units of Karuna Therapeutics Inc stock worth over 10,550,272$ and over the last 7 years he sold KRTX stock worth over 3,444,150$. In addition, he makes 941,899$ as Chief Financial Officer at Karuna Therapeutics Inc.
Troy has made over 26 trades of the Karuna Therapeutics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 1,500 units of KRTX stock worth 13,800$ on 22 August 2023.
The largest trade he's ever made was exercising 16,500 units of Karuna Therapeutics Inc stock on 15 November 2022 worth over 151,800$. On average, Troy trades about 6,777 units every 42 days since 2018. As of 22 August 2023 he still owns at least 31,987 units of Karuna Therapeutics Inc stock.
You can see the complete history of Mr. Ignelzi stock trades at the bottom of the page.
Troy A. Ignelzi serves as Chief Financial Officer of the Company. He has served as our Chief Financial Officer since March 2019. Prior to that, Mr. Ignelzi was the Chief Financial Officer of scPharmaceuticals Inc. from March 2016 to February 2019, and provided consulting services to scPharmaceuticals Inc. in February and March 2016. Mr. Ignelzi previously served as Chief Financial Officer and as a member of the executive leadership teams at Juventas Therapeutics Inc., a privately held biotechnology company, from October 2014 to February 2016. From October 2013 to October 2014, Mr. Ignelzi served as Senior Vice President—Operations and Business Development of Pharmalex GmbH. Prior to Pharmalex, Mr. Ignelzi was Vice President—Business Development at Esperion Therapeutics, Inc., a public pharmaceutical company, from January 2009 to September 2013. Mr. Ignelzi served as Vice President, Business Development & Strategic Planning at Insys Therapeutics, Inc., a specialty pharmaceutical company, from February 2007 to February 2009. Previously, Mr. Ignelzi had served as a specialty senior sales representative at Eli Lilly from February 2002 to August 2005. Mr. Ignelzi holds a B.S. in Accounting from Ferris State University.
As the Chief Financial Officer of Karuna Therapeutics Inc, the total compensation of Troy Ignelzi at Karuna Therapeutics Inc is 941,899$. There are 3 executives at Karuna Therapeutics Inc getting paid more, with Steven Paul having the highest compensation of 10,050,700$.
Troy Ignelzi is 52, he's been the Chief Financial Officer of Karuna Therapeutics Inc since 2019. There are 13 older and 2 younger executives at Karuna Therapeutics Inc. The oldest executive at Karuna Therapeutics Inc is Dr. Steven M. Paul M.D., 70, who is the CEO, Pres & Chairman.
Troy's mailing address filed with the SEC is C/O KARUNA THERAPEUTICS, INC., 99 HIGH STREET, 26TH FLOOR, BOSTON, MA, 02110.
Over the last 5 years, insiders at Karuna Therapeutics Inc have traded over 496,938,545$ worth of Karuna Therapeutics Inc stock and bought 1,501,936 units worth 53,814,390$ . The most active insiders traders include Health Llc Pure Tech、James Healy、Robert Nelsen. On average, Karuna Therapeutics Inc executives and independent directors trade stock every 12 days with the average trade being worth of 18,341,187$. The most recent stock trade was executed by Stephen K. Brannan on 8 March 2024, trading 7,500 units of KRTX stock currently worth 636,600$.
we are an innovative clinical-stage biopharmaceutical company primarily focused on developing novel therapies to address disabling neuropsychiatric conditions characterized by significant unmet medical need. our pipeline is built on the broad therapeutic potential of our lead product candidate, karxt, an oral modulator of muscarinic receptors that are located both in the central nervous system, or cns, and various peripheral tissues. karxt is our proprietary product candidate that combines xanomeline, a novel muscarinic agonist, with trospium, an approved muscarinic antagonist, to preferentially stimulate muscarinic receptors in the cns. we have assembled a team with extensive expertise in the research, development and commercialization of numerous cns agents, as well as deep familiarity with the biology of neuropsychiatric disorders, such as schizophrenia and ad, including the role of muscarinic receptors in their potential treatment. we will leverage this expertise to develop a pip
Karuna Therapeutics Inc executives and other stock owners filed with the SEC include: